Repository logo
 

Multiple Gastric Cancer Tissue Proteomic Identification Predicts CLU as a Biomarker for Anti-PD-1 Immunotherapy

Simple item page
aut.relation.articlenumber101615
aut.relation.endpage101615
aut.relation.journalJournal of Pharmaceutical Analysis
aut.relation.startpage101615
dc.contributor.authorZhang, Yu
dc.contributor.authorZhu, Hao-Yi
dc.contributor.authorMa, Cong-Cong
dc.contributor.authorWang, Ning
dc.contributor.authorLi, Yan
dc.contributor.authorLu, Guo-Liang
dc.contributor.authorDai, Xing-Jie
dc.contributor.authorWang, Bo
dc.contributor.authorMamun, MAA
dc.contributor.authorLi, Ying
dc.contributor.authorZhao, Xiao-Ying
dc.contributor.authorPang, Jing-Ru
dc.contributor.authorGuo, Ning-Jie
dc.contributor.authorQi, Feng-Yu
dc.contributor.authorSun, Jian-Gang
dc.contributor.authorLiu, Hong-Min
dc.contributor.authorLiu, Feng-Wu
dc.contributor.authorHerdewijn, Piet
dc.contributor.authorZhao, Long-Fei
dc.contributor.authorZheng, Yi-Chao
dc.date.accessioned2026-04-12T20:49:45Z
dc.date.available2026-04-12T20:49:45Z
dc.date.issued2026-04
dc.description.abstractHighlights • Clusterin (CLU) is a new negative predictive biomarker for anti-PD-1 immunotherapy of gastric cancer (GC). • CLU is a pivotal regulator of both tumor-intrinsic proliferation and immune evasion in GC. • CLU abrogation in GC enhances the immune response, boosting T-cell killing ability activity and cytokine secretion.
dc.identifier.citationJournal of Pharmaceutical Analysis, ISSN: 2095-1779 (Print), Elsevier BV, 101615-101615. doi: 10.1016/j.jpha.2026.101615
dc.identifier.doi10.1016/j.jpha.2026.101615
dc.identifier.issn2095-1779
dc.identifier.urihttp://hdl.handle.net/10292/20903
dc.languageen
dc.publisherElsevier BV
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S2095177926000705
dc.rights.accessrightsOpenAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject32 Biomedical and Clinical Sciences
dc.subject3211 Oncology and Carcinogenesis
dc.subject3204 Immunology
dc.subjectBiotechnology
dc.subjectRare Diseases
dc.subjectDigestive Diseases
dc.subjectPrecision Medicine
dc.subjectCancer
dc.subjectStomach Cancer
dc.subjectImmunization
dc.subjectImmunotherapy
dc.subjectVaccine Related
dc.subject5.1 Pharmaceuticals
dc.subject4.1 Discovery and preclinical testing of markers and technologies
dc.subject4.2 Evaluation of markers and technologies
dc.subjectCancer
dc.titleMultiple Gastric Cancer Tissue Proteomic Identification Predicts CLU as a Biomarker for Anti-PD-1 Immunotherapy
dc.typeJournal Article
pubs.elements-id757952

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Multiple gastric cancer tissue proteomic identification predicts CLU as a biomarker for anti-PD-1 immunotherapy.pdf
Size:
18.53 MB
Format:
Adobe Portable Document Format
Description:
Journal article
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Plain Text
Description:
Download

Collections

School of Science - Te Kura Pūtaiao